Supernus Pharmaceuticals, Inc.

NASDAQ:SUPN

31.52 (USD) • At close June 30, 2025
Bedrijfsnaam Supernus Pharmaceuticals, Inc.
Symbool SUPN
Munteenheid USD
Prijs 31.52
Beurswaarde 1,764,792,192
Dividendpercentage 0%
52-weken bereik 25.55 - 40.28
Industrie Drug Manufacturers—Specialty & Generic
Sector Healthcare
CEO Mr. Jack A. Khattar
Website https://www.supernus.com

An error occurred while fetching data.

Over Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis

Vergelijkbare Aandelen

Dynavax Technologies Corporation logo

Dynavax Technologies Corporation

DVAX

9.92 USD

Vaxcyte, Inc. logo

Vaxcyte, Inc.

PCVX

32.51 USD

Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc.

XENE

31.3 USD

Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc.

TVTX

14.8 USD

Krystal Biotech, Inc. logo

Krystal Biotech, Inc.

KRYS

137.46 USD

ImmunityBio, Inc. logo

ImmunityBio, Inc.

IBRX

2.64 USD

Establishment Labs Holdings Inc. logo

Establishment Labs Holdings Inc.

ESTA

42.71 USD

Addus HomeCare Corporation logo

Addus HomeCare Corporation

ADUS

115.19 USD

Ligand Pharmaceuticals Incorporated logo

Ligand Pharmaceuticals Incorporated

LGND

113.68 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)